BaroFold, among other assets, has developed PreEMT technology, which improves the quality of manufacturing biopharma products and decreases manufacturing costs (by as much as US$2-10mln per year per commercial biologic drug), the firm said.
Pressure BioSciences has developed unique and superior pressure cycling technology (PCT) to prepare biological lab samples.
"This acquisition will significantly increase PBI's IP estate in high-pressure technologies with the addition of eight issued and several pending patents," said Alexander Lazarev, vice-president of R&D for PBI.
"These patents give us freedom to operate in several important areas for biologics research and manufacturing: protein folding, re-folding and disaggregation.
"They also provide us the right to grant licenses to third parties to practice the PreEMT and other technologies in both research laboratories and in biopharmaceutical manufacturing, the latter being a very large and rapidly growing field."
Dr Nathan Lawrence, of Pressure BioSciences, added: "Importantly, our existing high-pressure equipment is well-suited to the performance of the R&D and process development studies needed for the development of these biopharmaceutical manufacturing applications and markets.
"In fact, it will quickly become evident that our new, award-winning Barocycler 2320EXT high-pressure instrument was designed with technologies like PreEMT bench scale R&D in mind.
"With our worldwide customer base, supported by our expanded sales and marketing capabilities and our growing equipment and consumables product lines, we believe the newly-acquired BaroFold IP will have a significant impact on our revenues in 2018 and beyond."
Pressure BioSciences shares are down 4.50% to US$3.82 in New York.